Gonadorelin: Uses, Mechanism, and Clinical Trial Data

Key takeaways

• Gonadorelin has a registered clinical trial footprint of 1,345 studies.
• Its chemical identity is cataloged under PubChem CID 638793.
• The compound has been studied in oncology contexts, including prostate cancer treatment combinations.
• Trial designs span early-phase and later-phase work, with varying completion status.

What gonadorelin is

Gonadorelin is a synthetic peptide with the molecular formula C55H75N17O13 and a molecular weight of about 1,182.3. Its structure is built from a chain of amino acid residues linked in sequence, consistent with peptides that interact with hormone-related signaling pathways. No further label-based mechanism detail is available here beyond its chemical identity.

What the evidence shows

Gonadorelin appears across 1,345 registered clinical trials, reflecting broad research interest over time. Among the sampled studies, one phase 1/phase 2 trial examined docetaxel, androgen ablation, and external-beam radiation therapy in patients with high-risk localized prostate cancer, and it reached completed status. A separate phase 2 trial looked at chemotherapy, hormone therapy, and radiation therapy in patients with locally advanced prostate cancer and was also completed. A phase 3 trial comparing tranexamic acid with norethisterone acetate on endometrial vasculature is listed with unknown status.